

Dai Horiuchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4014575/publications.pdf>

Version: 2024-02-01

7
papers

636
citations

1307594

7
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

1661
citing authors

#	ARTICLE	IF	CITATIONS
1	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. <i>Journal of Experimental Medicine</i> , 2012, 209, 679-696.	8.5	309
2	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. <i>Nature Medicine</i> , 2016, 22, 1321-1329.	30.7	138
3	Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1019-27.	7.1	64
4	Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17543-17550.	7.1	54
5	Taking on Challenging Targets: Making MYC Druggable. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e497-e502.	3.8	49
6	NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity. <i>Free Radical Biology and Medicine</i> , 2018, 126, 358-371.	2.9	12
7	Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. <i>Cell Chemical Biology</i> , 2022, 29, 358-372.e5.	5.2	10